Martinsried/Munich, February 5, 2009. The biotech company MediGene AG (Frankfurt, Prime Standard: MDG) has been selected for inclusion on the TecDAX, an index of the Frankfurt Stock Exchange including Germany’s most important mid-cap technology companies. The TecDAX follows the blue chip DAX index and comprises 30 companies admitted to the stock market “Prime Standard” segment. In addition to compliance with comprehensive international transparency requirements, the admission criteria include an above-average market capitalization (share price multiplied by the number of company shares), and a high trading volume (number of shares traded daily). According to the decision made by the German Stock Exchange on February 5, 2009, MediGene has fulfilled the admission criteria for the TecDAX and will be included there as of February 09, 2009.
Dr. Peter Heinrich, Chief Executive Officer of MediGene AG, comments: “TecDAX membership signifies MediGene’s position among the leading German technology securities. This admission is a reflection of MediGene’s dynamic growth and achievement in the biotechnology sector. The TecDAX listing increases MediGene’s visibility in the capital markets and facilitates our collaboration with domestic and international investors.”
This press release contains forward-looking statements representing the opinion of MediGene as of the date of this release. The actual results achieved by MediGene may differ significantly from the statements made herein. MediGene is not bound to update any of these forward-looking statements. MediGene® is a registered trademark of MediGene AG. This trademark may be owned or licensed in select locations only.
MediGene AG is a publicly listed (Frankfurt, Prime Standard: MDG) biotechnology company located in Martinsried/Munich, Germany, with subsidiaries in Oxford, UK and San Diego, USA. MediGene is the first German biotech company to have drugs on the market, which are being distributed by partner companies and has several drug candidates in clinical development, two of which provide significant sales potential. In addition, the company has numerous projects in research and pre-clinical development and possesses innovative platform technologies. MediGene focuses on the research and development of novel drugs for the treatment of cancer and autoimmune diseases.
Contact MediGene AG E-mail: investor@medigene.com Fax: +49 - 89 - 85 65 - 2920 Julia Hofmann / Dr. Nadja Wolf, Public Relations, Tel.: +49 - 89 - 85 65 - 3324 Dr. Georg Dönges, Investor Relations, Tel.: +49 - 89 - 85 65 - 2946
